CA2239203A1 - Drug therapy - Google Patents

Drug therapy Download PDF

Info

Publication number
CA2239203A1
CA2239203A1 CA002239203A CA2239203A CA2239203A1 CA 2239203 A1 CA2239203 A1 CA 2239203A1 CA 002239203 A CA002239203 A CA 002239203A CA 2239203 A CA2239203 A CA 2239203A CA 2239203 A1 CA2239203 A1 CA 2239203A1
Authority
CA
Canada
Prior art keywords
substance
molecule
ring
compound
conversion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA002239203A
Other languages
English (en)
French (fr)
Inventor
Tariq Khan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzacta R&D Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2239203A1 publication Critical patent/CA2239203A1/en
Pending legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02Monothiocarbamic acids; Derivatives thereof
    • C07C333/04Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/38One sulfur atom
CA002239203A 1995-12-06 1996-12-06 Drug therapy Pending CA2239203A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9524942.1A GB9524942D0 (en) 1995-12-06 1995-12-06 Drug therapy
GB9524942.1 1995-12-06

Publications (1)

Publication Number Publication Date
CA2239203A1 true CA2239203A1 (en) 1997-06-12

Family

ID=10784998

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002239203A Pending CA2239203A1 (en) 1995-12-06 1996-12-06 Drug therapy

Country Status (5)

Country Link
EP (1) EP0865298A1 (it)
JP (1) JP2000502071A (it)
CA (1) CA2239203A1 (it)
GB (1) GB9524942D0 (it)
WO (1) WO1997020580A1 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
CA2344440A1 (en) * 1998-09-18 2000-03-30 Immunomedics, Inc. Antibody directed enzyme prodrug therapy (edept) with glucoronidase
IL126732A0 (en) * 1998-10-23 1999-08-17 Intelligene Ltd Pro drug
GB0916749D0 (en) * 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy

Also Published As

Publication number Publication date
GB9524942D0 (en) 1996-02-07
WO1997020580A1 (en) 1997-06-12
EP0865298A1 (en) 1998-09-23
JP2000502071A (ja) 2000-02-22

Similar Documents

Publication Publication Date Title
US11278627B2 (en) Antibody-drug conjugates and the use of same in therapy
JP3592711B2 (ja) 細胞毒性剤治療
Melton et al. Antibody-enzyme conjugates for cancer therapy
US5728868A (en) Prodrugs of protein tyrosine kinase inhibitors
EP0408546B1 (en) Improvements relating to drug delivery systems
EP2709667B1 (en) Bio-orthogonal drug activation
US6511663B1 (en) Tri- and tetra-valent monospecific antigen-binding proteins
JP3373849B2 (ja) 3価および4価の単一特異性抗原結合性タンパク質
JP3983799B2 (ja) 細胞および血清タンパク質アンカー並びに接合体
AU2002337954B2 (en) Integrin targeting compounds
WO2014081301A1 (en) Bio-orthogonal drug activation
US5716990A (en) Drug delivery systems
CA2239203A1 (en) Drug therapy
CA2124217A1 (en) Inactivation of cytotoxic drugs
EP0918545B1 (en) Tumour therapy
Hay et al. Antibody-directed enzyme-prodrug therapy (ADEPT)
Knox et al. Antibody-directed enzyme prodrug therapy: potential in cancer
CA2177644A1 (en) Polymeric prodrugs for beta-lactamase and uses thereof
CA2344440A1 (en) Antibody directed enzyme prodrug therapy (edept) with glucoronidase
US20020127229A1 (en) Tumour therapy
MXPA96001871A (en) Polymeric profarmacos for the beta-lactamasa yusos de los mis

Legal Events

Date Code Title Description
FZDE Dead
FZDC Correction of dead application (reinstatement)